REDA, Gianluigi, Ramona CASSIN, Gabriela DOVRTĚLOVÁ, Cristina MATTEO, Juri GIANNOTTA, Maurizio D'INCALCI, Agostino CORTELEZZI a Massimo ZUCCHETTI. Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement. Haematologica. Itálie: Ferrata Storti Foundation, 2019, roč. 104, č. 5, s. "E222-E223", 2 s. ISSN 0390-6078. Dostupné z: https://dx.doi.org/10.3324/haematol.2018.213157. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1524093, author = {Reda, Gianluigi and Cassin, Ramona and Dovrtělová, Gabriela and Matteo, Cristina and Giannotta, Juri and D'Incalci, Maurizio and Cortelezzi, Agostino and Zucchetti, Massimo}, article_location = {Itálie}, article_number = {5}, doi = {http://dx.doi.org/10.3324/haematol.2018.213157}, keywords = {CNS involvement; Chronic Lymphocytic Leukemia; venetoclax}, language = {eng}, issn = {0390-6078}, journal = {Haematologica}, title = {Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement}, url = {http://www.haematologica.org/content/early/2019/02/07/haematol.2018.213157.abstract}, volume = {104}, year = {2019} }
TY - JOUR ID - 1524093 AU - Reda, Gianluigi - Cassin, Ramona - Dovrtělová, Gabriela - Matteo, Cristina - Giannotta, Juri - D'Incalci, Maurizio - Cortelezzi, Agostino - Zucchetti, Massimo PY - 2019 TI - Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement JF - Haematologica VL - 104 IS - 5 SP - "E222-E223" EP - "E222-E223" PB - Ferrata Storti Foundation SN - 03906078 KW - CNS involvement KW - Chronic Lymphocytic Leukemia KW - venetoclax UR - http://www.haematologica.org/content/early/2019/02/07/haematol.2018.213157.abstract L2 - http://www.haematologica.org/content/early/2019/02/07/haematol.2018.213157.abstract N2 - Venetoclax, a selective inhibitor of BCL2, has shown promising efficacy in chronic lymphocytic leukemia (CLL) both as single agent or in combination therapy. Central nervous system involvement (CNSi) is a rare complication of CLL and is reported in approximately 0.4% of patients. Therapeutic guidelines have not yet been established and prognosis for these patients is poor. Few cases of CLL with CNSi have been reported until now, and ibrutinib was successfully used due to its ability to penetrate the blood-brain barrier. ER -
REDA, Gianluigi, Ramona CASSIN, Gabriela DOVRTĚLOVÁ, Cristina MATTEO, Juri GIANNOTTA, Maurizio D'INCALCI, Agostino CORTELEZZI a Massimo ZUCCHETTI. Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement. \textit{Haematologica}. Itálie: Ferrata Storti Foundation, 2019, roč.~104, č.~5, s.~''E222-E223'', 2 s. ISSN~0390-6078. Dostupné z: https://dx.doi.org/10.3324/haematol.2018.213157.
|